<div id="readability-page-1">Elanco Animal Health (NYSE:ELAN - Get Free Report) had its price target increased by equities researchers at JPMorgan Chase &amp; Co. from $28.00 to $30.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price target indicates a potential upside of 25.03% from the company's previous close.<div>Get Elanco Animal Health alerts:</div><ul><li>Bullish or Bearish? Vetting Animal Health Care Stocks</li></ul>A number of other research analysts also recently issued reports on the company. Citigroup initiated coverage on Elanco Animal Health in a report on Wednesday, April 15th. They set a &#34;buy&#34; rating and a $30.00 price target on the stock. KeyCorp increased their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, February 25th. Weiss Ratings raised Elanco Animal Health from a &#34;sell (d)&#34; rating to a &#34;sell (d+)&#34; rating in a report on Monday, April 27th. UBS Group restated a &#34;buy&#34; rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, Piper Sandler upgraded Elanco Animal Health from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and upped their price target for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $28.10.Read Our Latest Research Report on Elanco Animal Health<h2>Elanco Animal Health Stock Down 8.3%</h2><ul><li>Zoetis Declares New Dividend, Hinting At Undervaluation</li></ul>NYSE:ELAN traded down $2.19 during trading hours on Thursday, reaching $24.00. 8,155,888 shares of the company traded hands, compared to its average volume of 5,021,183. The business's 50-day moving average price is $23.85 and its two-hundred day moving average price is $23.33. The stock has a market capitalization of $11.93 billion, a P/E ratio of -50.20, a P/E/G ratio of 2.93 and a beta of 1.69. Elanco Animal Health has a 1 year low of $11.83 and a 1 year high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company's quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts predict that Elanco Animal Health will post 1.03 earnings per share for the current year. <h2>Hedge Funds Weigh In On Elanco Animal Health</h2><ul><li>2 Contrarian Stock Picks With Major Upside</li></ul>Hedge funds have recently made changes to their positions in the business. UBS Group AG boosted its stake in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company's stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company's stock valued at $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Invesco Ltd. boosted its stake in Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company's stock valued at $108,376,000 after buying an additional 3,690,735 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Elanco Animal Health during the first quarter valued at approximately $66,390,000. Finally, Artemis Investment Management LLP bought a new position in Elanco Animal Health during the fourth quarter valued at approximately $55,693,000. Institutional investors own 97.48% of the company's stock. <h2>Key Stories Impacting Elanco Animal Health</h2>Here are the key news stories impacting Elanco Animal Health this week:<ul> <li>Positive Sentiment: Quarterly beat — Elanco reported Q1 adjusted EPS of $0.40 (vs. $0.34 consensus) and revenue of $1.371B (+15% YoY; 10% organic), with adjusted EBITDA of $334M and improving margins. These results validate the company’s innovation-led growth. Elanco Animal Health Reports First Quarter 2026 Results</li> <li>Positive Sentiment: Upgraded full-year targets — Elanco raised FY2026 guidance (revenue to $5.010B–$5.085B, adjusted EBITDA to $975M–$1,005M, adjusted EPS to $1.03–$1.09) and raised its innovation revenue target to $1.2B; management also tightened year-end net leverage goals to ~3.0–3.2x. These lifts are supportive of forward earnings growth. Elanco Animal Health Reports First Quarter 2026 Results</li> <li>Positive Sentiment: Regulatory/product momentum — The company announced emergency use authorizations for Negasunt Powder and Tanidil, supporting near-term product revenue and pipeline proof points that investors value. Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum</li> <li>Neutral Sentiment: Earnings materials available — Full earnings call transcript and the investor presentation/slide deck were released (useful for details on segments, geography and margin drivers). Elanco Q1 2026 Earnings Call Transcript Q1 Results - Earnings Call Presentation</li> <li>Negative Sentiment: Q2 guide slightly soft vs. consensus — Elanco guided Q2 EPS to $0.250–$0.285 vs. a consensus near $0.29 (revenues roughly in line). That miss on the midpoint may have trimmed near-term expectations and contributed to profit-taking after the rally. Elanco Animal Health Reports First Quarter 2026 Results</li> </ul><h2>About Elanco Animal Health</h2> (Get Free Report)Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention. Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.<h2>Recommended Stories</h2><ul><li>Five stocks we like better than Elanco Animal Health</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Elanco Animal Health Right Now?</h2>Before you consider Elanco Animal Health, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

ELAN

JPMorgan Chase & Co. has raised its price target for Elanco Animal Health (NYSE:ELAN) from $28.00 to $30.00, maintaining an "overweight" rating. This new target suggests a potential upside of 25.03% from the previous close. Other analysts have also issued positive ratings, with an average rating of "Moderate Buy" and a price target of $28.10. Elanco's stock recently traded down to $24.00, despite a strong quarterly earnings report showing $0.40 EPS, beating estimates. Institutional investors hold 97.48% of the company's stock.

Market Beat

Elanco Animal Health

JPMorgan Chase

Citigroup

KeyCorp

UBS Group AG

Piper Sandler Cos

Zoetis

T. Rowe Price

Invesco

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

Elanco Animal Health (NYSE:ELAN) Given New $30.00 Price Target at JPMorgan Chase & Co.